PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-6.32
Negative P/E while Biotechnology median is -5.64. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
-95.28
Negative equity while Biotechnology median P/B is 2.95. Seth Klarman would investigate balance sheet restructuring potential.
-109.82
Negative FCF while Biotechnology median P/FCF is -22.91. Seth Klarman would investigate cash flow improvement potential.
-110.52
Negative operating cash flow while Biotechnology median P/OCF is -22.20. Seth Klarman would investigate operational improvement potential.
-95.28
Negative fair value while Biotechnology median is 2.94. Seth Klarman would investigate valuation model issues.
-3.96%
Negative earnings while Biotechnology median yield is -1.90%. Seth Klarman would investigate path to profitability.
-0.91%
Negative FCF while Biotechnology median yield is -1.17%. Seth Klarman would investigate cash flow improvement potential.